Intellia Therapeutics, Inc. (NTLA) on GreekSoup https://greeksoup.ai/stocks/us/ntla/ Every dated entry in the public record on Intellia Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 Intellia Therapeutics, Inc.: short interest 44,435,219 shares at the 15 October 2026 settlement, 6.45 days to coverhttps://greeksoup.ai/stocks/us/ntla/short-interest/us:NTLA:short-interest:2026-10-15:2331261ca3Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: Dube Michael P (VP, Chief Accounting Officer) sold 1,864 shares at $12.43 on 2 October 2026, $23,170https://greeksoup.ai/stocks/us/ntla/insiders/us:NTLA:insider:2026-10-06:ab7ce8a17aTue, 06 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: Form 144, ELIANA CLARK plans to sell 57,750 shares worth $736,312 around 5 October 2026https://greeksoup.ai/stocks/us/ntla/planned-sales/us:NTLA:planned-sale:2026-10-05:46d3f41a38Mon, 05 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: short interest 45,110,513 shares at the 30 September 2026 settlement, 9.47 days to coverhttps://greeksoup.ai/stocks/us/ntla/short-interest/us:NTLA:short-interest:2026-09-30:2790ceda6fWed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: short interest 46,681,609 shares at the 15 September 2026 settlement, 14.10 days to coverhttps://greeksoup.ai/stocks/us/ntla/short-interest/us:NTLA:short-interest:2026-09-15:a3358d21edTue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/ntla/filings/us:NTLA:filing:2026-09-08:d84e77fbadTue, 08 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc. filed 8-K: material agreement, new financial obligation, regulation fd disclosurehttps://greeksoup.ai/stocks/us/ntla/filings/us:NTLA:filing:2026-09-04:eb1e7bb515Fri, 04 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: short interest 43,928,014 shares at the 31 August 2026 settlement, 12.89 days to coverhttps://greeksoup.ai/stocks/us/ntla/short-interest/us:NTLA:short-interest:2026-08-31:8ca60a3caeMon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: Leonard John M (President and CEO) sold 2,785 shares (under a trading plan set in advance) at $13.00 on 21 August 2026, $36,205https://greeksoup.ai/stocks/us/ntla/insiders/us:NTLA:insider:2026-08-24:b85acee695Mon, 24 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: Leonard John M (President and CEO) sold 19,890 shares (under a trading plan set in advance) at $12.60 on 20 August 2026, $250,614https://greeksoup.ai/stocks/us/ntla/insiders/us:NTLA:insider:2026-08-24:bb5b60711fMon, 24 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: Form 144, LEONARD JOHN M plans to sell 22,675 shares worth $293,641 around 20 August 2026https://greeksoup.ai/stocks/us/ntla/planned-sales/us:NTLA:planned-sale:2026-08-20:a858b313cfThu, 20 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: short interest 44,880,339 shares at the 14 August 2026 settlement, 13.15 days to coverhttps://greeksoup.ai/stocks/us/ntla/short-interest/us:NTLA:short-interest:2026-08-14:f9d91c79fbFri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: Schedule 13G filed by STATE STREET CORPORATION, 6.8% of the classhttps://greeksoup.ai/stocks/us/ntla/holders/us:NTLA:schedule-13:2026-08-07:1ab899ae5aFri, 07 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc. Q2 FY2026 results: revenue $8 million, net income -$107 millionhttps://greeksoup.ai/stocks/us/ntla/results/fy2026-q2/us:NTLA:result:2026-08-06:468cda07a1Thu, 06 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/ntla/filings/us:NTLA:filing:2026-08-06:91e885800bThu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/ntla/filings/us:NTLA:filing:2026-08-06:cfe48b8e29Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Intellia Therapeutics, Inc.: short interest 44,010,769 shares at the 31 July 2026 settlement, 11.96 days to coverhttps://greeksoup.ai/stocks/us/ntla/short-interest/us:NTLA:short-interest:2026-07-31:89e9eae488Fri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>